Ferit ÇELİK, Ali ŞENKAYA, Füsun SAYGILI, Özgür FIRAT, Hayriye ELBİ, Rukiye VARDAR

Single-center retrospective evaluation of short and long-term efficacy of intragastric balloon placement in obesity treatment

Obesity is a serious chronic disease caused by genetic and environmental factors. One of the treatment options is intragastric balloon application. This study aimed to evaluate the results of patients who underwent intragastric balloon placement on the short- and long-term treatment of obesity. The data and long-term follow-up results of 34 patients who underwent intragastric balloon placement due to obesity between December 2011 and August 2013 were retrospectively evaluated. Age, sex, body mass index (BMI), presence of additional diseases, duration of intragastric balloon remaining in the stomach, patients’ weight, and BMI at intragastric balloon removal, weight measured in December 2019, bariatric surgery performed during the study period if any, and general health status during this period were obtained. The mean weight loss of the patients after intragastric balloon removal was 15.6 ± 9.6 kg (range, 0–45 kg). The mean decrease in BMI after intragastric balloon removal was 11.4 ± 6.4% (range, 0%–26.5%). No patients developed any complications. The procedure was ineffective in the long-term in 76.4% of the patients. The most important disadvantage of intragastric balloon placement application in the treatment of obesity is that the weight lost in the early period is regained in the long-term after balloon removal. In patients scheduled to undergo bariatric surgery, intragastric balloon placement can be applied as a bridge therapy to facilitate preoperative weight loss to reduce complications.

PDF

___

1. Caglar E, Dobrucali A, Bal K. Gastric balloon to treat obesity: Filled with air or fluid? Dig Endosc. 2013;25:502-7.

2. Gaur S, Levy S, Mathus-Vliegen L, et al. Balancing risk andreward: a critical review of the intragastric balloon for weight loss. Gastrointest Endosc. 2015;81:1330–36.

3. Lau DC, Teoh H. Benefits of modest weight loss on the management of type 2 diabetes mellitus. Can J Diabetes. 2013;37:128–34.

4. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:1-253.

5. Dastis NS, François E, Deviere J, et al. Intragastric balloon for weight loss: results in 100 individuals followed for at least 2.5 years. Endoscopy. 2009;41:575-80.

6. Sullivan S. Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterol. 2017;152:1791-801.

7. Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment resistant obesity: safety, tolrance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19-27.

8. Martins Fernandes FA Jr, Carvalho GL, et al. Intragastric balloon for overweight patients. JSLS. 2016;20:2015.

9. Stanford FC, Kyle TK, Claridy MD, et al. The influence of an individual's weight perception on the acceptance of bariatric surgery. Obesity. 2015;23:277-81.

10. Göttig S, Weiner RA, Daskalakis M. Preoperative weight reduction using the intragastric balloon. ObesFacts. 2009;2:20-3.

11. Bor S, Turan İ, Özütemiz Ö. A case of balloon rupture during insertion of an intragastric balloon for treatment of morbid obesity. Akademik Gastroenteroloji Dergisi. 2007;6:94-6.

12. Fleisher A, Conti PS, McCray RS, et al. Jejunal entrapment of a gastric balloon. JAMA. 1987;257:930.

13. Genco A, Bruni T, Doldi SB, et al. Bio Enterics intragastric balloon: The Italian experience with 2,515 patients. Obes Surg. 2005;15:1161-4.

14. Fernandes M, Atallah AN, Soares BGO, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;24:004931.

15. Lopez-Nava G, Bautista-Castaño I, Jimenez-Baños A, et al. Dual intragastric balloon: single ambulatory center Spanish experience with 60 patients in endoscopic weight loss management. Obes surg. 2015;25:2263-7.

16. Frutos, Maria Dolores, Luján J, et al. Intragastric balloon reduces liver volume in super-obese patients, facilitating subsequent laparoscopic gastric bypass. Obes surg. 2007;17:150-4.

17. Milone L, Strong V, Gagner M. Laparoscopic sleeve gastrectomy is superior to endoscopic intragastric balloon as a first stage procedure for super-obese patients (BMI≥ 50). Obes surg. 2005;15:612-7.

18. Aren A. Morbid obezite tedavisinde ıntragastrik balon uygulaması. Istanbul Tıp Dergisi. 2007;3:16-9.

19. Bayraktar O, Özçelik AA, Öktemgil AR, et al. Intragastric balloon therapy for obesity: Is it safe and effective? Arch Clin Exp Med. 2019;4:25-8.

20. Yorke E, Switzer NJ, Reso A, et al. Intragastric balloon for management of severe obesity: a systematicr eview. Obes surg. 2016;26:2248-54.

21. Brunaldi VO, Galvao Neto M. Endoscopic techniques for weight loss and treating metabolic syndrome. Curr Opin Gastroenterol. 2019;35:424-31.

22. Behary J, Kumbhari V. Advances in the endoscopic management of obesity. Gastroenterol Res and Pract. 2015;2015:757821.

23. López-Nava G, Bautista-Castaño I, Jimenez A, et al. The primary obesity surgery endolumenal (POSE) procedure: one-year patient weight loss and safety outcomes. Surg Obes Relat Dis. 2015;11:861-65.

24. Lopez-Nava G, Galvão MP, Bautista-Castaño I, et al. Endoscopic sleeve gastroplasty for obesity treatment: two years of experience. ABCD. Arq Bras de Cir Dig. 2017;30:18-20.

25. Afridi AK, Khan A. Prevalence and etiology of obesity-An overview. Pakistan Nutrit. 2004;3:14-25.

26. Frellick M. Obesity type factors into weight loss success. https://www. medscape.com/viewarticle/925703 access date 27.07.2020.